Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 1.00 |
| ▸ | DDB1 | Q16531 | 19/20 | 1.00 |
| ▸ | BRD4 | O60885 | 15/20 | 1.00 |
| ▸ | BRD3 | Q15059 | 1/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 1/20 | 1.00 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.99 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.99 |
| ▸ | BET1 | O15155 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30146573 | 1.00 | CRBN (1.00) | CRBNDDB1BRD4BRD3BRDT | |
| SCHEMBL19556879 | 1.00 | CRBN (1.00) | CRBNDDB1BRD4BRD3BRDT | |
| SCHEMBL19556893 | 1.00 | CRBN (1.00) | CRBNDDB1BRD4BRD3BRDT | |
| SCHEMBL29566239 | 1.00 | CRBN (1.00) | CRBNDDB1BRD4BRD3BRDT | |
| SCHEMBL19556887 | 1.00 | CRBN (1.00) | CRBNDDB1BRD4BRD3BRDT | |
| SCHEMBL19556839 | 1.00 | CRBN (1.00) | CRBNDDB1BRD4BRD3BRDT | |
| SCHEMBL17553399 | 1.00 | CRBN (1.00) | CRBNDDB1BRD4BRD3BRDT | |
| SCHEMBL19556892 | 1.00 | CRBN (1.00) | CRBNDDB1BRD4BRD3BRDT | |
| SCHEMBL23789740 | 0.99 | CRBN (1.00) | CRBNDDB1BRD4BRD3BRDT | |
| SCHEMBL17859001 | 0.99 | CRBN (1.00) | CRBNDDB1BRD4BRD3BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4119552-A1 | REGULATING CHIMERIC ANTIGEN RECEPTORS | Dana-Farber Cancer Institute, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20210301286-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11046954-B2 | Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210015929-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10849980-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200317635-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20180085465-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-03-29 | — | — | US | disclosed |
| US-9821068-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9770512-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9750816-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9694084-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| WO-2017024319-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20160243247-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160235731-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160235730-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243247-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885BRD4 687/4885 |
| US-20210301286-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | NFATC1, GZMB, ICOS | CRBN 97/4885DDB1 940/4885BRD4 2934/4885 |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885BRD4 687/4885 |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, XIAP, MDM2 | CRBN 1/4885DDB1 110/4885BRD4 1005/4885 |
| US-20160235731-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885BRD4 687/4885 |
| US-11046954-B2 | Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses | NFATC1, GZMB, ICOS | CRBN 97/4885DDB1 940/4885BRD4 2934/4885 |
| US-20210015929-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885BRD4 687/4885 |
| US-20160235730-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885BRD4 687/4885 |
| US-20180085465-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885BRD4 687/4885 |
| US-20200317635-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885BRD4 687/4885 |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885BRD4 687/4885 |
| US-10849980-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885BRD4 687/4885 |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | CRBN 138/4885DDB1 26/4885BRD4 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.